← Product Code [LIT](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/LIT) · K970299 # JUPITER PTA CATHETERS (VARIOUS) (K970299) _Cordis Corp. · LIT · Apr 24, 1997 · Cardiovascular · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/LIT/K970299 ## Device Facts - **Applicant:** Cordis Corp. - **Product Code:** [LIT](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/LIT.md) - **Decision Date:** Apr 24, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 870.1250 - **Device Class:** Class 2 - **Review Panel:** Cardiovascular - **Attributes:** Therapeutic ## Indications for Use Jupiter PTA Catheters are designed for dilating stenotic atherosclerotic lesions in peripheral arteries (renal, popliteal, infra popliteal, femoral, and ilio femoral) and are also intended to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. ## Device Story Jupiter PTA Catheters; percutaneous transluminal angioplasty balloon catheters; used by physicians in clinical settings for dilation of stenotic atherosclerotic lesions in peripheral arteries and obstructive lesions in arteriovenous dialysis fistulae; device functions via mechanical balloon inflation to restore vessel patency; provides clinical benefit by improving blood flow in peripheral vasculature. ## Clinical Evidence No clinical data; bench testing only. Biocompatibility testing performed in compliance with ISO 10993. ## Technological Characteristics PTA balloon catheter; materials consistent with previously cleared Jupiter PTA Catheters (K955886); biocompatibility per ISO 10993. ## Regulatory Identification A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire. ## Predicate Devices - Jupiter PTA Catheters (Cordis Corporation) - Opta 5 PTA Catheters (Cordis Corporation) - Ultra Thin PTA Balloon Catheter (Medi Tech) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 000048 PREMARKET NOTIFICATION 510(k) Cordis Corporation Jupiter PTA Catheters January 24, 1997 APR 24 1997 K970299 # Attachment 1 # SUMMARY OF SAFETY AND EFFECTIVENESS ## I. General Provisions: Common Name: Percutaneous Transluminal Angioplasty Catheters Proprietary Name: Jupiter PTA Catheters ## II. Name of Predicate Devices: a. Trade Name: Jupiter PTA Catheters Manufacturer: Cordis Corporation b. Trade Name: Opta 5 PTA Catheters Manufacturer: Cordis Corporation c. Trade Name: Ultra Thin PTA Balloon Catheter Manufacturer: Medi Tech ## III. Classification: Class II ## IV. Performance Standards: Performance standards have not been established by the FDA under Section 514 of the Food, Drug and Cosmetic Act. ## V. Intended Use and Device Description: Jupiter PTA Catheters are designed for dilating stenotic atherosclerotic lesions in peripheral arteries (renal, popliteal, infra popliteal, femoral, and ilio femoral) and are also intended to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. 1. A statement of substantial equivalence to another product is required by 21 CFR 807.87, and relates only to whether the present product can be marketed without prior reclassification or clinical approval. The present submission is therefore not related to the coverage of any patent and is not to be interpreted as an admission or used as evidence in a patent infringement lawsuit. As the commissioner of the FDA has stated, "A determination of substantial equivalence under the Federal Food, Drug and Cosmetic Act related to the fact that the product can be lawfully marketed without pre-market approval or reclassification. This determination is not intended to have any bearing whatsoever on the resolution of patent infringement suits" 42 Fed. Reg. 42, 520 et seq. (1977). {1} 00004 PREMARKET NOTIFICATION 510(k) Cordis Corporation Jupiter PTA Catheters January 24, 1997 ## VI. Biocompatibility Since no new materials are being introduced in this submission, no additional biocompatibility testing was performed. All appropriate biocompatibility tests were successfully performed on Cordis Corporation's Jupiter PTA Catheters. Biocompatibility test results can be found in K955886. Biocompatibility testing was performed in compliance with ISO Standard 10993. ## VII. Summary of Substantial Equivalence: Jupiter PTA Catheters are substantially equivalent to the predicate devices. Jupiter PTA Catheters are similar in design, construction, indications for use, and performance characteristics as compared to commercially available PTA Catheters. --- **Source:** [https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/LIT/K970299](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/LIT/K970299) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com